BioSpace News Archive

NCLA Submits Comment to HHS and CMS Critical of Rulemaking

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NurOwn® for the treatment of progressive multiple sclerosis (MS).

Suspected opioid overdoses and deaths continue to rise in Arizona. The total number of deaths (counted since 2017) jumped 55 percent in the past three months, from 1,645 in Aug. 2018 to 2,547 in Nov. 2018

Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patients in its 1801 Phase 1 / 2 study of 9-ING-41, a proprietary glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in patients with refractory hematologic malignancies or solid tumors.

Below is a statement by United States Conference of Mayors President Columbia (SC) Mayor Steve Benjamin on U.S. District Court Judge Reed O’Connor’s ruling on the Affordable Care Act:

The 2018 results from the National Institute on Drug Abuse (NIDA) and University of Michigan’s annual drug abuse survey, Monitoring the Future, were released today showing that the percentage of teens using over-the-counter (OTC) cough medicine containing dextromethorphan (DXM) to get high remains at 3 percent.

Officials from Health Canada will hold a media technical briefing to discuss proposed regulatory measures for single-serve flavoured purified alcohol beverages.

Ruling invalidates critical health care protections for millions of people with pre-existing conditions

Calyxt, Inc. (NASDAQ: CLXT), a consumer-centric, food- and agriculture-focused company, today announced the issuance of European patent No. 3008186, which claims methods to create gene-edited plants by the transient delivery of sequence-specific nucleases, including CRISPR/Cas9.

HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI) announced today that it has entered into a revised Supply and License Agreement (SLA) with its majority stockholder Mayne Pharma Ventures Pty Ltd (Mayne Pharma), an affiliate of Mayne Pharma Group Limited (ASX: MYX).